Flag of the European Union EU Clinical Trials Register Help

Clinical trials for acne

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    181 result(s) found for: acne. Displaying page 3 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-002057-65 Sponsor Protocol Number: RD.03.SPR.40161E Start Date*: 2011-09-01
    Sponsor Name:Galderma R&D SNC
    Full Title: Effect of CD08100/02 3% gel versus placebo in subjects presenting with erythematotelangiectatic rosacea over a 4 week treatment period.
    Medical condition: Erythematotelangiectatic rosacea
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003796-58 Sponsor Protocol Number: NAC-GED-0507-ACN-02-17 Start Date*: 2017-12-13
    Sponsor Name:PPM SERVICES S.A.
    Full Title: AN OPEN LABEL CLINICAL STUDY TO EVALUATE THE LONG-TERM DERMAL SAFETY PROFILE OF 12-WEEKS TOPICAL ADMINISTRATION OF N-ACETYL-GED-0507-34-LEVO GEL 5% IN PATIENTS WITH FACIAL ACNE
    Medical condition: FACIAL ACNE
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022912-37 Sponsor Protocol Number: MP‐1501‐01 Start Date*: 2012-03-07
    Sponsor Name:Medicis Pharmaceutical Corporation [...]
    1. Medicis Pharmaceutical Corporation
    2. Dow Pharmaceutical Sciences
    Full Title: Multi-centre, open-label, long-term safety trial to assess the long-term safety of tretinoin clindamycin phosphate gel in patients from 12 to less than 18 years of age with acne vulgaris.
    Medical condition: Treatment of Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022918-15 Sponsor Protocol Number: 7001‐G2HP‐07‐02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences
    Full Title: Multi-centre, randomized, double-blind, active- and vehicle-controlled trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone, tretinoin ...
    Medical condition: Treatment of acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022919-20 Sponsor Protocol Number: MP-1501-02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences [...]
    1. Dow Pharmaceutical Sciences
    2. Medicis Pharmaceutical Corporation
    Full Title: Multi-centre, randomized, double-blind trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone in the treatment of acne vulgaris in patien...
    Medical condition: Treatment of Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022911-20 Sponsor Protocol Number: 7001‐G2HP‐06‐02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences
    Full Title: A Multi-Center, Phase 3, Randomized, Double-Blind, 4-Arm Clinical Trial to Compare the Safety and Efficacy of Clin-RA Gel vs. Clindamycin Phosphate 1.2% Gel vs. Tretinoin 0.025% Gel vs. Clin-RA Gel...
    Medical condition: Treatment of acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002623-26 Sponsor Protocol Number: CB-03-01/26 Start Date*: 2016-03-17
    Sponsor Name:CASSIOPEA SpA
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) 1% Cream Applied Twice-Daily for 12 Weeks in ...
    Medical condition: facial acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-005244-17 Sponsor Protocol Number: GED-0507-ACN-01-14 Start Date*: 2015-09-28
    Sponsor Name:PPM SERVICES S.A.
    Full Title: AN OPEN LABEL CLINICAL STUDY TO EVALUATE THE LONG-TERM DERMAL SAFETY PROFILE OF 12-WEEKS TOPICAL ADMINISTRATION OF TWO DIFFERENT DOSES OF N-ACETYL-GED-0507-34-LEVO GEL IN PATIENTS WITH MILD TO MODE...
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003070-23 Sponsor Protocol Number: CLITRETVER Start Date*: 2023-01-27
    Sponsor Name:Verisfield S.M.S.A.
    Full Title: A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence for the comparison of clindamycin + tretinoin/Verisfield gel (1+0.025)% with Acn...
    Medical condition: Acne Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000616-15 Sponsor Protocol Number: CB-03-01/28 Start Date*: 2016-05-25
    Sponsor Name:Cassiopea S.P.A.
    Full Title: An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <...
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003707-40 Sponsor Protocol Number: RD.03.SPR.40031 Start Date*: 2007-01-09
    Sponsor Name:Galderma Research and Development SNC
    Full Title: Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea.
    Medical condition: Erythemato-Telangiectatic Rosacea (ETR)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039218 Rosacea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000100-37 Sponsor Protocol Number: V01-126A-202 Start Date*: 2022-01-03
    Sponsor Name:Bausch Health Americas, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% adapalene/2.5% BPO), in the Treat...
    Medical condition: Acne Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-006050-51 Sponsor Protocol Number: RD.06.SPR.202395 Start Date*: 2021-08-03
    Sponsor Name:Galderma S.A.
    Full Title: Evaluation of the risk of atrophic acne scar formation during treatment of acne vulgaris subjects with trifarotene 50 µg/g cream versus vehicle cream over 24 weeks
    Medical condition: acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004998-83 Sponsor Protocol Number: MUS92579_2057_1 Start Date*: 2012-04-04
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A Double-Blind, Randomized, Dose Selection Vehicle–Controlled Multicenter Clinical Study for Evaluation of the Safety, Tolerability, Efficacy, and Pharmacokinetics of topical Neramexane in Subjects...
    Medical condition: Moderate to severe acne
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10000497 Acnes HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013273-17 Sponsor Protocol Number: KF03/08 Start Date*: Information not available in EudraCT
    Sponsor Name:Ichthyol-Gesellschaft Cordes, Hermanni & Co. (GmbH & Co.) KG
    Full Title: Double-blind, randomized, vehicle-controlled, multi-centric trial to prove the therapeutic efficacy and tolerability of a liquid acne topical containing Clindamycin phosphate and Sodiumbituminosulf...
    Medical condition: mild to moderate acne vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-001575-23 Sponsor Protocol Number: 201884 Start Date*: 2017-09-21
    Sponsor Name:GlaxoSmithKline KK
    Full Title: Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese Subjects.
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018399 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-002359-26 Sponsor Protocol Number: S194-401 Start Date*: 2008-11-19
    Sponsor Name:Stiefel Laboratories
    Full Title: A multi-center, randomized, evaluator-blind, parallel group study evaluation of the efficacy, safety, and tolerability of DUAC® Akne Gel and Epiduo® Gel in the topical treatment of facial acne vu...
    Medical condition: acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003156-37 Sponsor Protocol Number: RD.03.SPR.40037 Start Date*: 2006-10-13
    Sponsor Name:Galderma Research and Development SNC
    Full Title: AN EXPLORATORY STUDY TO EVALUATE RELAPSES FOLLOWING AN INITIAL 12 WEEKS DOSE-RANGE STUDY WITH CD5024 CREAM VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM IN PAPULO-PUSTULAR ROSACEA – A 6 M...
    Medical condition: Subject who was successfully treated for his/her papulo-pustular rosacea in the initial study (Galderma Study: Eudract N°: 2006-001999-20/RD.03.SPR.40027)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001999-20 Sponsor Protocol Number: RD.03.SPR.40027 Start Date*: 2006-10-10
    Sponsor Name:Galderma Research & Development SNC
    Full Title: ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (RO...
    Medical condition: Patients with papulo-pustular rosacea
    Disease: Version SOC Term Classification Code Term Level
    9.0 10039218 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000152-42 Sponsor Protocol Number: BS-HAU-2011001 Start Date*: 2011-07-07
    Sponsor Name:Medical Faculty, University Magdeburg
    Full Title: An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren 15% gel and Differin 0.1 % gel for the treatment and maintenance treatment of facial acne vulgaris and l...
    Medical condition: Acne vulgaris late type acne
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 21:09:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA